Fladrafinil Dosage: Is There an Established Human Dose?

There is no clinically established human dose of fladrafinil for cognition, wakefulness, fatigue, or another therapeutic purpose.

A 2026 peer-reviewed human study examined how fladrafinil is metabolised and eliminated, while an older Lafon patent reported repeated oral administration in humans.[1,2] The two sources provide useful evidence about human exposure, but neither was designed as a modern clinical dose-finding trial.

What Dose Has Actually Been Studied in Humans?

In a 2026 Drug Testing and Analysis study, Krug and colleagues administered a single 20 mg dose of fladrafinil to six healthy volunteers, three men and three women.[1]

Participants also received a single 20 mg dose of flmodafinil during a separate study period, with a three-week washout between administrations. Blood and urine samples were collected to identify the parent compounds and their metabolites and to characterise their elimination for anti-doping testing.[1]

The study did not compare different fladrafinil doses, measure changes in memory or attention, test wake-promoting efficacy, determine a maximum tolerated dose, or investigate repeated long-term use.[1]

Where Does the 100–150 mg Fladrafinil Dose Come From?

A patent filed by Laboratoire L. Lafon for CRL-40,941 and related compounds describes oral human administration using two or three capsules or tablets containing 50 mg each per day.[2]

That corresponds to 100–150 mg per day. The patent states that treatment lasted between two and eight weeks and refers to use in conditions including hypersomnia and psychasthenia.[2]

Why the Patent Does Not Establish a Clinical Dose

The patent does not report a clear participant count, demographic characteristics, randomisation procedure, placebo group, predefined clinical endpoints, statistical analysis, detailed adverse-event data, pharmacokinetic measurements, or a comparison between multiple human doses.[2]

Its statement that favourable results were observed in humans therefore cannot be evaluated in the same way as findings from a modern clinical trial.

What Do Animal Studies Tell Us About Fladrafinil Dosage?

In the Lafon patent, mouse and rat experiments tested CRL-40,941 at doses including 16, 64, 128, and 256 mg/kg, depending on the experiment.[2]

For example, the patent reports that 64 and 128 mg/kg reduced the duration of barbital-induced sleep in mice.[2]

Many of these experiments used intraperitoneal injection, involved different species, and measured experimental behavioural endpoints rather than therapeutic outcomes in humans. Those differences make the animal doses unsuitable for direct conversion into an oral human regimen.

Applying a standard body-surface-area calculation could generate a numerical human-equivalent dose, but it would not establish equivalent drug exposure, pharmacological effects, or safety in people.

Does Fladrafinil Convert to Flmodafinil?

After participants received fladrafinil in the 2026 study, researchers detected flmodafinil, flmodafinil acid, and flmodafinil sulfone in biological samples.[1]

Flmodafinil concentrations also peaked later after fladrafinil administration, consistent with conversion of fladrafinil to flmodafinil in vivo.[1]

While these metabolism data support the prodrug relationship between the compounds, they do not provide a clinical dose-conversion factor.

Can Fladrafinil Doses Be Extrapolated From Modafinil or Adrafinil?

There is no validated milligram-for-milligram conversion between fladrafinil and modafinil or between fladrafinil and adrafinil.

Fladrafinil belongs to the same broader chemical family and is a fluorinated analogue of adrafinil. A 2020 review of emerging cognitive enhancers identified fladrafinil alongside adrafinil, flmodafinil, and related modafinil-family compounds circulating in the online nootropics environment.[3]

Chemical similarity does not establish equal potency, absorption, bioavailability, metabolism, or drug exposure. Because the 2026 human study focused on metabolism and anti-doping detection rather than therapeutic equivalence, established modafinil or adrafinil dosages cannot be converted into fladrafinil equivalents on the basis of structural similarity alone.[1]

What Did the Study Find About Commercial Product Concentrations?

The fladrafinil solution used in the 2026 study was labelled as containing 100 mg/mL, but laboratory analysis measured 93.1 mg/mL.[1]

The researchers adjusted the administered volume so participants still received the intended 20 mg dose.

The flmodafinil product showed a larger discrepancy, labelled at 50 mg/mL but measured at 95.7 mg/mL.[1]

These findings came from two specific commercially obtained products and should not be treated as representative of the wider fladrafinil or flmodafinil market. They do show that the researchers verified product concentration analytically rather than assuming the labels were accurate.

Has a Safe Fladrafinil Dose Been Established?

The available human literature does not establish a maximum tolerated dose, safe repeated-use range, adverse-effect frequency, long-term interaction profile, or chronic safety threshold for fladrafinil.

The Lafon patent describes repeated administration but provides little detailed safety reporting.[2] The modern human study involved only six participants and single-dose exposure.[1]

A small metabolism study cannot determine the safety of repeated daily use or identify uncommon adverse effects that would require substantially larger clinical studies to detect.

Why Are Fladrafinil Dosages Published Online?

In 2020, Napoletano and colleagues identified fladrafinil among substances discussed or marketed online for cognitive enhancement through the NPSfinder web-monitoring project.[3]

Online dose figures may come from the Lafon patent, comparisons with modafinil or adrafinil, vendor descriptions, or individual self-experimentation. These sources have very different evidentiary value and should not be treated as equivalent to clinical dose-ranging research.

What Does the Evidence Actually Support?

Human exposure to fladrafinil is documented more clearly than it once was. The 2026 study provides directly measured human metabolism and elimination data, while the older Lafon patent records an earlier period of repeated human administration.[1,2]

What remains missing is a clinical dose-response evidence base: no adequate human trials have defined the amount needed to produce a cognitive or wake-promoting effect, established a validated conversion from related compounds, or determined a safe repeated-use range.

For that reason, there is currently no established evidence-based human dose of fladrafinil.

References

1. Krug, O., Guddat, S., Görgens, C., Thomas, A., & Thevis, M. (2026). Investigations into the metabolism and elimination of flmodafinil and fladrafinil for sports drug testing purposes. Drug Testing and Analysis, 18(8), 1076–1087. https://doi.org/10.1002/dta.70100
2. Lafon Laboratories. (1984). Halogenobenzhydrylsulfinylacetohydroxamic acids (U.S. Patent No. 4,489,095).
3. Napoletano, F., Schifano, F., Corkery, J. M., Guirguis, A., Arillotta, D., Zangani, C., & Vento, A. (2020). The psychonauts’ world of cognitive enhancers. Frontiers in Psychiatry, 11, 546796. https://doi.org/10.3389/fpsyt.2020.546796